OncLive TV

Ajay K. Nooka, MD, MPH, FACP, discusses the integration of bispecific antibodies into the community treatment paradigm for multiple myeloma.

Matthew Lawrence Inra, MD, discusses the role of the thoracic surgeon in treatment decision-making for patients with early-stage lung cancer.

David S. Miller, MD, discusses the efficacy of selinexor in patients with advanced or recurrent TP53 wild-type endometrial cancer.

Tony S. K. Mok, BMSc, MD, FASCO, discusses efficacy findings from a pooled analysis of the TRUST-I and TRUST-II trials of taletrectinib in ROS1+ NSCLC.

Tanios Bekaii-Saab, MD, FACP, discusses the evolving treatment paradigm for BRCA1- and BRCA2-positive pancreatic cancer in the first-line setting.

Farrukh Awan, MD, discuses the evolving role of bispecific antibodies in the treatment paradigm of diffuse large B-cell lymphoma.

Minoo Battiwalla, MD, MS, discusses both the benefits and the limitations of treatment with CAR T-cell therapy across hematologic malignancies.

Cynthia X. Ma, MD, PhD, discusses positive interim data from the phase 1 ReDiscover trial in PI3Kα-mutated HR-positive, HER2-negative breast cancer.

Jyoti Patel, MD, discusses the implications of the TRUST-II trial in locally advanced or metastatic ROS1-positive NSCLC, regardless of prior TKI exposure.

Leo I. Gordon, MD, discusses the clinical implications of findings from the mantle cell lymphoma cohort of the TRANSCEND NHL 001 trial evaluating liso-cel.

Bertram Yuh, MD, MISM, MSHCPM, discusses the role of genetic factors, such as BRCA mutations, in the risk stratification of patients with prostate cancer.

Alexander Drilon, MD, discusses efficacy findings from the TRUST-I and TRUST-II trials in patients with ROS1+ non–small cell lung cancer.

David Rimm, MD, discusses the current limitations of immunohistochemistry diagnostic kits for HER2-low and HER2-ultralow breast cancer.

Laahn Ho Foster, MD, discusses the potential role of daratumumab plus lenalidomide maintenance in multiple myeloma after ASCT.

David C. Fisher, MD, discusses resistance mechanisms observed among patients with CLL who were previously treated with covalent BTK inhibitors.

Michel Ducreux, MD, PhD, discusses the rationale for the TRANSMET trial in patients with CRC liver metastases, highlighting the significance of data from the trial.

Meletios A. Dimopoulos, MD, discusses patient-reported outcomes with BPd in pretreated patients with relapsed/refractory multiple myeloma.

Terence W. Friedlander, MD, discusses the design and methodology of the Duravelo-2 study of zelenectide pevedotin in advanced/metastatic urothelial cancer.

Sandra Mazzoni, DO, discusses the emerging role of quadruplet regimens in newly diagnosed multiple myeloma.

Binod Dhakal, MD, discusses the design of the CARTITUDE-4 study investigating cilta-cel in relapsed/refractory multiple myeloma.

Jorge E. Cortes, MD, discusses efficacy and safety findings from the phase 4 BYOND study in previously treated patients with Ph+ chronic myeloid leukemia.

Nicolas Girard, MD, discusses finding from the LUMINOSITY trial in c-Met protein–overexpressing, EGFR wild-type, non–small cell lung cancer.

Sunil Adige, MD, discusses aspects of post-treatment care that can improve long-term quality of life and reduce the risk of breast cancer recurrence.

Minoo Battiwalla, MD, MS, discusses the potential of FLT3-ITD and menin inhibitors to broaden the acute myeloid leukemia treatment paradigm.

Samuel J. Klempner, MD, discusses the FDA approval of zolbetuximab for CLDN18.2+, HER2–, locally advanced unresectable or metastatic gastric/GEJ adenocarcinoma.

Jill Corre, PharmD, PhD, discusses the implications of using daratumumab plus bortezomib, thalidomide, and dexamethasone in newly diagnosed myeloma.

Chad Tang, MD, discusses unanswered questions surrounding the role of radiation therapy in renal cell carcinoma.

Grzegorz S. Nowakowski, MD, discusses the potential implications of the TakeAim Lymphoma trial of emavusertib plus ibrutinib in patients with PCNSL.

Leo I. Gordon, MD, discusses future steps for optimizing the use of lisocabtagene maraleucel in the treatment of relapsed/refractory mantle cell lymphoma.

Terence W. Friedlander, MD, discusses emerging agents of interest in urothelial carcinoma.